Adjunctive therapies in severe sepsis and septic shock: Current place of steroids

Current Infectious Disease Reports

Volumn 10, Issue 5, 2008, Pages 354-361

  Keh, Didier ^a   Weber Carstens, Steffen ^b   Ahlers, Olaf ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CORTICOSTEROID; CORTICOTROPIN; DEXAMETHASONE; FLUDROCORTISONE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; HYDROCORTISONE; HYPERTENSIVE FACTOR; INSULIN; METHYLPREDNISOLONE; MUSCLE RELAXANT AGENT; PLACEBO;

ADJUVANT THERAPY; ADRENAL FUNCTION; ADRENAL INSUFFICIENCY; ADULT RESPIRATORY DISTRESS SYNDROME; APACHE; ARTIFICIAL VENTILATION; BOLUS INJECTION; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONTINUOUS INFUSION; CRITICAL ILLNESS RELATED CORTICOSTEROID INSUFFICIENCY; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; FLUID THERAPY; HUMAN; HYPERGLYCEMIA; HYPERNATREMIA; HYPERTENSION; HYPOPHYSIS ADRENAL SYSTEM; LOW DRUG DOSE; MORTALITY; MUSCLE WEAKNESS; NONHUMAN; PRACTICE GUIDELINE; REVIEW; RISK FACTOR; RISK REDUCTION; SEPSIS; SEPTIC SHOCK; SUPERINFECTION; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

EID: 63249086551     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-008-0058-z     Document Type: Review

References (50)

1. Lefering R, Neugebauer EA: Steroid controversy in sepsis and septic shock: A meta-analysis. Crit Care Med 1995, 23:1294-1303.
2. Annane D, Bellissant E, Bollaert PE, et al.: Corticosteroids for treating severe sepsis and septic shock. Cochrane Database Syst Rev 2004, CD002243.
3. Minneci PT, Deans KJ, Banks SM, et al.: Meta-analysis: the effect of steroids on survival and shock during sepsis depends on the dose. Ann Intern Med 2004, 141:47-56.
4. Dellinger RP, Levy MM, Carlet JM, et al.: Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 2008, 34:17-60.
5. Marik PE, Pastores SM, Annane D, et al.: Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: Consensus statements from an international task force by the American College of Critical Care Medicine. Crit Care Med 2008, 36:1937-1949.
6. Dellinger RP, Carlet JM, Masur H, et al.: Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Intensive Care Med 2004, 30:536-555.
7. Annane D, Sebille V, Charpentier C, et al.: Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002, 288:862-871.
8. Cooper MS, Stewart PM: Adrenal insufficiency in critical illness. J Intensive Care Med 2007, 22:348-362.
9. Annane D, Sebille V, Troche G, et al.: A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. JAMA 2000, 283:1038-1045.
10. Annane D, Maxime V, Ibrahim F, et al.: Diagnosis of adrenal insufficiency in severe sepsis and septic shock. AmJ Respir Crit Care Med 2006, 174:1319-1326.
11. Huh JW, Lim CM, Koh Y, Hong SB: Effect of low doses of hydrocortisone in patients with septic shock and relative adrenal insufficiency: 3 days versus 7 days treatment [abstract]. Crit Care Med 2006, 34:A101.
12. Sprung CL, Annane D, Keh D, et al.: Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008, 358:111-124.
13. Arafah BM: Hypothalamic pituitary adrenal function during critical illness: Limitations of current assessment methods. J Clin Endocrinol Metab 2006, 91:3725-3745.
14. Eichacker PQ, Parent C, Kalil A, et al.: Risk and the efficacy of antiinflammatory agents: Retrospective and confirmatory studies of sepsis. Am J Respir Crit Care Med 2002, 166:1197-1205.
15. Li Y, Cui X, Li X, et al.: Risk of death does not alter the efficacy of hydrocortisone therapy in a mouse E. coli pneumonia model: Risk and corticosteroids in sepsis. Intensive Care Med 2008, 34:568-577.
16. Cicarelli DD, Vieira JE, Bensenor FE: Early dexamethasone treatment for septic shock patients: A prospective randomized clinical trial. Sao Paulo Med J 2007, 125:237-241.
17. Mikami K, Suzuki M, Kitagawa H, et al.: Efficacy of corticosteroids in the treatment of community-acquired pneumonia requiring hospitalization. Lung 2007, 185:249-255.
18. Meduri GU, Yates CR: Systemic inflammation-associated glucocorticoid resistance and outcome of ARDS. Ann N Y Acad Sci 2004, 1024:24-53.
19. Meduri GU, Muthiah MP, Carratu P, et al.: Nuclear factor-kappaB-and glucocorticoid receptor alpha-mediated mechanisms in the regulation of systemic and pulmonary inflammation during sepsis and acute respiratory distress syndrome. Evidence for inflammation-induced target tissue resistance to glucocorticoids. Neuroimmunomodulation 2005, 12:321-338.
20. Bornstein SR, CArousos GP: Clinical review 104: adrenocorticotropin (ACTH)-and non-ACTH-mediated regulation of the adrenal cortex: Neural and immune inputs. J Clin Endocrinol Metab 1999, 84:1729-1736.
21. Confalonieri M, Urbino R, Potena A, et al.: Hydrocortisone infusion for severe community-acquired pneumonia: A preliminary randomized study. Am J Respir Crit Care Med 2005, 171:242-248.
22. Meduri GU, Golden E, Freire AX, et al.: Methylprednisolone infusion in early severe ARDS: Results of a randomized controlled trial. Chest 2007, 131:954-963.
23. Steinberg KP, Hudson LD, Goodman RB, et al.: Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med 2006, 354:1671-1684.
24. Meduri GU, Headley AS, Golden E, et al.: Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: A randomized controlled trial. JAMA 1998, 280:159-165.
25. Annane D, Sebille V, Bellissant E: Effect of low doses of corticosteroids in septic shock patients with or without early acute respiratory distress syndrome. Crit Care Med 2006, 34:22-30.
26. Meduri GU, Marik PE, Ahrousos GP, et al.: Steroid treatment in ARDS: a critical appraisal of the ARDS network trial and the recent literature. Intensive Care Med 2008, 34:61-69.
27. Agarwal R, Nath A, Aggarwal AN, Gupta D: Do glucocorticoids decrease mortality in acute respiratory distress syndrome? A meta-analysis. Respirology 2007, 12:585-590.
28. Peter JV, John P, Graham PL, et al.: Corticosteroids in the prevention and treatment of acute respiratory distress syndrome (ARDS) in adults: meta-analysis. BMJ 2008, 336:1006-1009.
29. Oppert M, Schindler R, Husung C, et al.: Low-dose hydrocortisone improves shock reversal and reduces cytokine levels in early hyperdynamic septic shock. Crit Care Med 2005, 33:2457-2464.
30. Hermans G, Wilmer A, Meersseman W, et al.: Impact of intensive insulin therapy on neuromuscular complications and ventilator dependency in the medical intensive care unit. AmJ RespirCrit Care Med 2007, 175:480-489.
31. Kellum JA, Kong L, Fink MP, et al.: Understanding the inflammatory cytokine response in pneumonia and sepsis: Results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. Arch Intern Med 2007, 167:1655-1663.
32. Yende S, D'Angelo G, Kellum JA, et al.: Inflammatory markers at hospital discharge predict subsequent mortality after pneumonia and sepsis. Am J Respir Crit Care Med 2008, 177:1242-1247.
33. Keh D, Boehnke T, Weber-Carstens S, et al.: Immunologic and hemodynamic effects of "low-dose" hydrocortisone in septic shock: A double-blind, randomized, placebo-controlled, crossover study. Am J Respir Crit Care Med 2003, 167:512-520.
34. Briegel J, Kellermann W, Forst H, et al.: Low-dose hydrocortisone infusion attenuates the systemic inflammatory response syndrome. The Phospholipase A2 Study Group. Clin Investig 1994, 72:782-787.
35. Van den Berghe G, Wouters P, Weekers F, et al.: Intensive insulin therapy in the critically ill patients. N Engl J Med 2001, 345:1359-1367.
36. Van den Berghe G, Wilmer A, Hermans G, et al.: Intensive insulin therapy in the medical ICU. N Engl J Med 2006, 354: 449-461.
37. Brunkhorst FM, Engel C, Bloos F, et al.: Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008, 358:125-139.
38. Krinsley JS: Effect of an intensive glucose management protocol on the mortality of critically ill adult patients. Mayo Clin Proc 2004, 79:992-1000.
39. Krinsley JS: Association between hyperglycemia and increased hospital mortality in a heterogeneous population of critically ill patients. Mayo Clin Proc 2003, 78:1471-1478.
40. Finney SJ, Zekveld C, Elia A, Evans TW: Glucose control and mortality in critically ill patients. JAMA 2003, 290:2041-2047.
41. Egi M, Bellomo R, Stachowski E, et al.: Variability of blood glucose concentration and short-term mortality in critically ill patients. Anesthesiology 2006, 105:244-252.
42. Annane D, Bellissant E, Bollaert PE, et al.: Corticosteroids for severe sepsis and septic shock: A systematic review and meta-analysis. BMJ 2004, 329:480.
43. Loisa P, Parviainen I, Tenhunen J, et al.: Effect of mode of hydrocortisone administration on glycemic control in patients with septic shock: A prospective randomized trial. Crit Care 2007, 11:R21.
44. Weber-Carstens S, Deja M, Bercker S, et al.: Impact of bolus application of low-dose hydrocortisone on glycemic control in septic shock patients. Intensive Care Med 2007, 33:730-733.
45. Ahlers O, Sprung CL, Briegel J, et al.: Immune effects of hydrocortisone in septic shock: Results from the CORTICUS Berlin Study Group. Intensive Care Med 2007, 33:S5.
46. De Jonghe B, Sharshar T, Lefaucheur JP, et al.: Paresis acquired in the intensive care unit: A prospective multicenter study. JAMA 2002, 288:2859-2867.
47. Bolton CF: Neuromuscular manifestations of critical illness. Muscle Nerve 2005, 32:140-163.
48. Huang CJ, Lin HC: Association between adrenal insufficiency and ventilator weaning. Am J Respir Crit Care Med 2006, 173:276-280.
49. Alberti C, Brun-Buisson C, Goodman SV, et al.: Influence of systemic inflammatory response syndrome and sepsis on outcome of critically ill infected patients. Am J Respir Crit Care Med 2003, 168:77-84.
50. Bone RC, Fisher CJJ, Clemmer TP, et al.: A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 1987, 317:653-658.